NATALEE Data Shows Ribociclib Reduces Risk of Recurrence for High-Risk Node-Negative Early Breast Cancer

The addition of ribociclib (Kisqali; Novartis) to endocrine therapy demonstrated a 28% risk reduction in invasive disease-free survival.

Related Keywords

United States ,American ,Sebastian Kaulitzki ,Denisea Yardley ,Jeff Legos ,Aimee Keegan ,Sarah Cannon Research Institute ,Breast Cancer Research Executive Committee ,Global Head Of Oncology Development ,European Medicines Agency ,American Society Of Clinical Oncology ,Novartis ,Breast Cancer Research ,Pharmacy Times ,Clinical Oncology ,Annual Meeting ,Global Head ,Oncology Development ,